Most US adults with type 2 diabetes meet criteria for GLP-RAs, SGLT2is
Feb 28, 2023
More than 82% US adults with type 2 diabetes meet the criteria to be prescribed the drugs, yet only 9% use either of them.
Pfizer asks FDA to approve omicron-specific booster shot
Aug 22, 2022
The drug company says that its new mRNA vaccine produces an immune response against the BA.4 and BA.5 omicron subvariants.
More clinical benefits of molnupiravir ID’d in COVID-19
Jun 07, 2022
New benefits for certain COVID-19 patients, including reduced need for respiratory intervention, have been found for Merck’s COVID-19 pill molnupiravir.
Burden of persistent symptoms high after COVID-19 infection
May 24, 2022
– A high burden of persistent symptoms is observed in persons after COVID-19, but no specific causes of symptoms of postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)...
Potential moral injury seen in healthcare workers similar to vets
Apr 12, 2022
Demographic characteristics suggestive of less empowerment may increase risk for moral injury
FDA advisers weigh COVID-19 booster shots for fall
Apr 07, 2022
Vaccine experts still guessing at what the ever-changing pandemic will bring
COVID-19 rapid test makers struggling to meet demand
Jan 21, 2022
However, government’s order for the free test kits is in addition to existing supply and does not interfere with existing orders
Pfizer says final data show COVID-19 pill stays strong against severe illness
Dec 14, 2021
Latest results show that drug cuts hospitalizations, deaths by nearly 90 percent when taken within three to five days of the start of symptoms
Outcomes worse for hospitalized patients with incontinence
Dec 08, 2021
Outcomes even worse for hospitalized patients with incontinence who require treatment of incontinence-associated dermatitis
Risk factors ID’d for conversion from RIS to multiple sclerosis
Oct 18, 2021
For radiologically isolated syndrome, younger age, spinal cord lesions, gadolinium-enhancing lesions at time of index scan tied to increased risk